| Featured Catalyst Every Week |  | | A full report on a catalyst with the highest potential for success, based on quantitative and qualitative assessment. The report summarizes the science, regulatory factors, and recent events that influenced the stock’s price. Please refer to samples.
| Regular Updates to Pending Featured Catalysts | | | Companies can speed up or delay when they report catalysts. Regulatory decisions in Europe and the US can be completed earlier than forecast. SanaCurrents updates key actions related to every pending catalyst and when the catalyst is completed.
| Supporting Historical Table to Guide the Progress of Catalyst | | | The subscriber home page within SanaCurrents. Track the price of every catalyst report you receive. Refer back to previous catalyst reports and updates. Monitor the price movement related to catalyst results and catalyst outcomes, positive or negative.
| On the Horizon | |  | Not quite a Featured Catalyst, the catalysts sent out as On the Horizon events could yield spectacular results but also carry many red flag warnings. A successful Alzheimer’s drug trial would be an example. Dozens of companies have tried in the past decade. Some trial results certainly were promising, but none have delivered unequivocal data in phase III. Or reached the market.
| Advanced MACE scores | | | The SanaCurrents acronym MACE stands for Market demand, Adoption by Key Opinion Leaders (KOLs), Clinical Progress and Experience & Capital. SanaCurrents drills down and applies scores to more than 50 data points related to MACE. Subscribers gain more detailed insight into the strengths and weaknesses of Featured Catalysts.
| Basic Sentiment Rating | | | Based on SanaCurrents proprietary analytics, each Featured Catalyst receives a Sentiment Rating describing the probability of success. Superior is the highest sentiment rating, followed by Pivotal and Advantageous. Pivotal and Superior ratings have MACE scores higher than 60%.
| Immediate Full Access to All Existing Pending Catalysts | | | SanaCurrents typically has 15 to 25 pending catalysts outstanding. Upon subscription, institutional investors gain access to all pending catalysts in the Supporting Historical Table, thereby taking full advantage of SanaCurrents reports to guide investment decisions.
| Immediate Full Access to All Historical SanaCurrents Catalyst Reports | | | With nearly 125 SanaCurrents reports issued over the past four years, the SanaCurrents database is a reference to guide past and future investment decisions. Many companies within the SanaCurrents catalyst universe have grown to multi-billion valuations. SanaCurrents reports of a few years ago provide more context to decisions.
| 2 Free Reports + 3 More During Trial Period | N/A Since Full Access Provided | | Upon providing your email and a credit card, you will receive two SanaCurrents reports on pending catalysts at no charge. In addition, you will receive 3 more Featured Catalyst reports in the three weeks after you sign up for a subscription. If you decide to cancel within the 3-week trial period, your credit card will not be charged for either the quarterly or annual subscription.
| Post-Catalyst Sentiment | | | Many Featured Catalysts involve companies providing proof of efficacy of a drug or device. Even if successful, more work lies ahead. The Post-Catalyst Sentiment – up, neutral or down – informs how well a company will navigate its next steps, based primarily on its pipeline and capital structure.
| Special Catalyst Reports Upon Request | | | At times, subscribers would like to know what a SanaCurrents MACE score would be for a catalyst within a company they are evaluating. SanaCurrents provides the MACE score or a full report to institutional subscribers upon request.
